Executive Summary

Cardero Therapeutics is dedicated to the development of first-in-class, therapeutics for orphan and rare diseases characterized by impairment of the skeletal muscle, cardiac, or neuronal systems. Many of these diseases, particularly muscular dystrophy and respiratory chain diseases, are associated with loss of mitochondrial number or function, depriving the affected tissues of the energy required for normal function. Cardero’s discovery of a previously unknown class of hormones that stimulate mitochondrial replacement and promote regeneration of muscle fibers and neurons have allowed the design of novel therapeutic drug candidates for previously untreatable diseases.